Paul Wagle, M.A., is the Director of Life Science Development for the lead economic agency in the state of Kansas. Mr. Wagle was diagnosed with leukemia at the age of 10, and after a four-year battle including an adult stem cell transplant, he has been cured for over 10 years. He holds a Master of Arts in Philosophical Studies, and serves as an advisor on two healthcare boards including the Midwest Stem Cell Therapy Center Advisory Board. Mr. Wagle is one of our nearly 40 associate scholars. In this interview, he discusses his experience with a life-saving adult stem cell treatment, and the importance of promoting ethical approaches to medical research. Watch a video of Paul Wagle’s story here.
Today the Charlotte Lozier Institute releases its sixth in its series of Stem Cell Research Facts videos. This story features the work of Dr. Joseph McGuirk, an adult stem cell expert at the University of Kansas Hospital, and tells the story of Chance Runnion’s recovery from leukemia after an adult stem cell transplant.
The law provides for 10 years of funding with $4.5 million approved for the first year and $4.35 million each year thereafter.
The Maryland Stem Cell Research Fund (MSCRF) has awarded two rounds of grants since the Charlotte Lozier Institute last analyzed the Fund’s pattern of grant making for stem cell research, in the fall of 2013.
Today the Charlotte Lozier Institute releases its fourth Stem Cell Research Facts video; this story features Cindy Schroeder’s recovery from multiple myeloma after an adult stem cell transplant.
A recent press release from the National Institutes of Health calls attention to a study, published in Stem Cell Reports, that researchers have “developed a clinical-grade stem cell line, which has the potential to accelerate the advance of new medical applications and cell-based therapies for millions of people suffering from such ailments as Alzheimer’s disease, Parkinson’s disease, spinal cord injury, diabetes, and muscular dystrophy.” The development of these clinical grade stem cells, the release notes, “removes a significant barrier in the development of cell-based therapies.” But is NIH’s promotion of “stem cells” anything new?